Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

Inclusion Criteria: * Subjects who were able and willing to give written informed consent. * Male or female subjects aged between 18 and 45 years, inclusive. * Subjects of body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive. * Subjects who were healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead ECG. * Subjects who had negative tests for HBsAg, anti-HCVAb and HIV-1 and HIV-2 Ab at screening * Subjects who had clinical laboratory test results clinically acceptable at screening and admission to each treatment period. * Subjects who had a negative screen for alcohol and drugs of abuse at screening and admission to each treatment period. * Subjects who were non-smokers or ex-smokers for at least 3 months. * (If female) She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: double barrier or intrauterine device. * (If female) She had a negative pregnancy test (β-HCG) at screening and admission to each treatment period. Exclusion Criteria: * Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular,psychiatric,musculoskeletal, genitourinary,immunological,dermatological,endocrine, connective tissue diseases or disorders. * Subjects who had a clinically relevant surgical history. * Subjects who had any significant abnormality in the coagulation tests. * Subjects who had any significant abnormality in the liver function tests (a case-by-case decision for any abnormality was to be discussed with the Sponsor before inclusion). * Subjects who had a history of relevant atopy or drug hypersensitivity. * Subjects who had a history of alcoholism or drug abuse. * Subjects who consumed more than 14 units of alcohol a week. * Subjects who had a significant infection or known inflammatory process at screening or admission to each treatment period. * Subjects who had acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period. * Subjects who had received fluoxetine within 5 weeks of admission to the first period. * Subjects who had used any other medicines within 2 weeks of admission to first period that could affected the safety or other study assessments, in the investigator's opinion. * Subjects who had previously received BIA 9-1067. * Subjects who have used any investigational drug or participated in any clinical trial within 90 days prior to screening. * Subjects who have donated or received any blood or blood products within the 3 months prior to screening. * Subjects who were vegetarians, vegans or have medical dietary restrictions. * Subjects who could not communicated reliably with the investigator. * Subjects who were unlikely to co-operate with the requirements of the study. * Subjects who were unwilling or unable to give written informed consent. * (If female) She was pregnant or breast-feeding. * (If female) She was of childbearing potential and she did not use an approved effective contraceptive method (double-barrier, intra-uterine device) or she uses oral contraceptives.